Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pBabe-Kras G12C Citations (7)

Originally described in: Mutant Ras Constructs
Unpublished

Articles Citing pBabe-Kras G12C

Articles
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24. PubMed
Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. Wang ZD, Wei SQ, Wang QY. Am J Cancer Res. 2015 Oct 15;5(11):3339-49. eCollection 2015. PubMed
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, Kojima S, Takeyama R, Hashimoto T, Kiyono T, Ikemura M, Taguchi A, Tanaka T, Tanaka Y, Sakata S, Takeuchi K, Muraoka A, Osuka S, Saito T, Oda K, Osuga Y, Terao Y, Kawazu M, Mano H. Nat Commun. 2019 Dec 19;10(1):5785. doi: 10.1038/s41467-019-13708-y. PubMed
A CRISPR-Cas9 repressor for epigenetic silencing of KRAS. Liu J, Sun M, Cho KB, Gao X, Guo B. Pharmacol Res. 2021 Feb;164:105304. doi: 10.1016/j.phrs.2020.105304. Epub 2020 Nov 14. PubMed
Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, Tandon V. Free Radic Biol Med. 2021 Dec;177:299-312. doi: 10.1016/j.freeradbiomed.2021.11.001. Epub 2021 Nov 3. PubMed
Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition. Huynh MV, Parsonage D, Forshaw TE, Chirasani VR, Hobbs GA, Wu H, Lee J, Furdui CM, Poole LB, Campbell SL. J Biol Chem. 2022 Aug;298(8):102186. doi: 10.1016/j.jbc.2022.102186. Epub 2022 Jun 24. PubMed
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Shin DH, Jo JY, Choi M, Kim KH, Bae YK, Kim SS. Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.